EUVIMEDEUVIMED entdecken
Crossref

Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups

Zifan Ji, Tingting Dai, Yixinyue Xu, Zilong Wang, Qian Zhang, Liang Zheng iD, Wei Hu

Naunyn-Schmiedeberg's Archives of Pharmacology · 29.10.2026

DOI: 10.1007/s00210-026-06018-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 29.10.2026. Verfasst von Zifan Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sumatriptan is a 5-hydroxytryptamine 1B/1D receptor agonist for acute migraine. Reduced organic cation transporter 1 (OCT1) function is associated with increased sumatriptan exposure, but its quantitative contribution to pharmacokinetic variability remains unclear. The aim of the study is to develop a whole-body physiologically based pharmacokinetic (PBPK) model describing sumatriptan PK across OCT1 functional groups and explore an exposure-matched candidate dose. A 50-mg mixed-genotype base model was developed from three clinical studies and extrapolated to 25 and 100 mg without reestimating drug-specific parameters. OCT1 functional differences were represented by changes in the effective OCT1-mediated hepatic uptake capacity ( V _max). Individuals with 0 active OCT1 alleles were compared with those with 1 or 2 active alleles. Oral doses of 20, 25, and 30 mg were explored in the 0-active-allele group using a predefined exposure-matching range of 0.80–1.25 for C _max and AUC_0-9 h. Across 50-mg studies, geometric mean fold errors were 1.25 for C _max, 1.07 for AUC_0-12 h, and 1.12 for T _max. Across 25- and 100-mg studies, predicted-to-observed ratios ranged from 0.65 to 1.50. After 50 mg, predicted C _max and AUC_0-9 h ratios for the 0-active-allele group relative to the 1-or-2-active-allele group were 1.81 and 1.82, compared with observed ratios of 1.77 and 2.20. Both 25 and 30 mg in the 0-active-allele group met the predefined exposure-matching criterion relative to 50 mg in the 1-or-2-active-allele group, whereas 20 mg did not. The PBPK model quantified OCT1-related variability in sumatriptan disposition and supported 25 mg as a clinically feasible exploratory candidate for prospective evaluation in the 0-active-allele group. Graphical Abstract

Schlagwörter

Stichwörter der Autor:innen

SLC22A1Organic cation transporter 1PharmacogenomicsPhysiologically based pharmacokinetic modelingSumatriptan

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
  • School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.
  • Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. zhengl@ahmu.edu.cn.
  • Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. huwei@ahmu.edu.cn.

ORCID-Profile: Liang Zheng

Zitieren

APA

Ji, Z., Dai, T., Xu, Y., Wang, Z., Zhang, Q., Zheng, L., & Hu, W. (2026). Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-06018-w

Vancouver

Ji Z, Dai T, Xu Y, Wang Z, Zhang Q, Zheng L, et al. Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-06018-w

BibTeX
@article{Ji2026,
  author = {Ji, Zifan and Dai, Tingting and Xu, Yixinyue and Wang, Zilong and Zhang, Qian and Zheng, Liang and Hu, Wei},
  title = {Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-06018-w}
}
Kostenlos starten →